Secondary analysis demonstrates pemafibrate reduces LDL-C and atherogenic lipids in MASLD patients, suggesting improved cardiovascular lipid profiles.
Pemafibrate reduced LDL-C, ApoB, and non-HDL-C levels in patients with MASLD, and the effect was greater in those with higher baseline LDL-C levels. Pemafibrate may clinically benefit patients with MASLD by improving LDL-C levels and the LDL particle profile.
No takes yet. Share an insight, caveat, or question.
Tanigawa et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: